234 related articles for article (PubMed ID: 36159878)
1. A role for an HTLV-1 vaccine?
Ratner L
Front Immunol; 2022; 13():953650. PubMed ID: 36159878
[TBL] [Abstract][Full Text] [Related]
2. Epitope-based universal vaccine for Human T-lymphotropic virus-1 (HTLV-1).
Raza MT; Mizan S; Yasmin F; Akash AS; Shahik SM
PLoS One; 2021; 16(4):e0248001. PubMed ID: 33798232
[TBL] [Abstract][Full Text] [Related]
3. Mother-to-Child Transmission of HTLV-1 Epidemiological Aspects, Mechanisms and Determinants of Mother-to-Child Transmission.
Percher F; Jeannin P; Martin-Latil S; Gessain A; Afonso PV; Vidy-Roche A; Ceccaldi PE
Viruses; 2016 Feb; 8(2):. PubMed ID: 26848683
[TBL] [Abstract][Full Text] [Related]
4. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
5. Tropical spastic paraparesis and HTLV-1 associated myelopathy: clinical, epidemiological, virological and therapeutic aspects.
Gessain A; Mahieux R
Rev Neurol (Paris); 2012 Mar; 168(3):257-69. PubMed ID: 22405461
[TBL] [Abstract][Full Text] [Related]
6. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
7. A Potential of an Anti-HTLV-I gp46 Neutralizing Monoclonal Antibody (LAT-27) for Passive Immunization against Both Horizontal and Mother-to-Child Vertical Infection with Human T Cell Leukemia Virus Type-I.
Fujii H; Shimizu M; Miyagi T; Kunihiro M; Tanaka R; Takahashi Y; Tanaka Y
Viruses; 2016 Feb; 8(2):. PubMed ID: 26848684
[TBL] [Abstract][Full Text] [Related]
8. Molecular determinants of human T-lymphotropic virus type 1 transmission and spread.
Lairmore MD; Anupam R; Bowden N; Haines R; Haynes RA; Ratner L; Green PL
Viruses; 2011 Jul; 3(7):1131-65. PubMed ID: 21994774
[TBL] [Abstract][Full Text] [Related]
9. Short communication an interferon-γ ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population.
Best I; López G; Talledo M; MacNamara A; Verdonck K; González E; Tipismana M; Asquith B; Gotuzzo E; Vanham G; Clark D
AIDS Res Hum Retroviruses; 2011 Nov; 27(11):1207-12. PubMed ID: 21453202
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of human T-lymphotropic virus type 1 transmission and disease.
Lairmore MD; Haines R; Anupam R
Curr Opin Virol; 2012 Aug; 2(4):474-81. PubMed ID: 22819021
[TBL] [Abstract][Full Text] [Related]
11. Advances in HTLV-1 peptide vaccines and therapeutics.
Lynch MP; Kaumaya PT
Curr Protein Pept Sci; 2006 Apr; 7(2):137-45. PubMed ID: 16611139
[TBL] [Abstract][Full Text] [Related]
12. A novel mother-to-child human T-cell leukaemia virus type 1 (HTLV-1) transmission model for investigating the role of maternal anti-HTLV-1 antibodies using orally infected mother rats.
Murakami Y; Hasegawa A; Ando S; Tanaka R; Masuda T; Tanaka Y; Kannagi M
J Gen Virol; 2017 Apr; 98(4):835-846. PubMed ID: 28150581
[TBL] [Abstract][Full Text] [Related]
13. Among all human T-cell leukemia virus type 1 proteins, tax, polymerase, and envelope proteins are predicted as preferential targets for the HLA-A2-restricted cytotoxic T-cell response.
Pique C; Connan F; Levilain JP; Choppin J; Dokhélar MC
J Virol; 1996 Aug; 70(8):4919-26. PubMed ID: 8763995
[TBL] [Abstract][Full Text] [Related]
14. Humoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individuals.
Enose-Akahata Y; Abrams A; Massoud R; Bialuk I; Johnson KR; Green PL; Maloney EM; Jacobson S
Retrovirology; 2013 Feb; 10():19. PubMed ID: 23405908
[TBL] [Abstract][Full Text] [Related]
15. Different B-cell responses to human T-cell lymphotropic virus type I (HTLV-I) envelope synthetic peptides in HTLV-I-infected individuals.
Ida H; Kurata A; Eguchi K; Kawakami A; Migita K; Fukuda T; Nakamura T; Kusumoto Y; Berzofsky JA; Nagataki S
J Clin Immunol; 1991 May; 11(3):143-51. PubMed ID: 1890164
[TBL] [Abstract][Full Text] [Related]
16. Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.
Kannagi M; Hasegawa A; Nagano Y; Kimpara S; Suehiro Y
Retrovirology; 2019 Aug; 16(1):23. PubMed ID: 31438973
[TBL] [Abstract][Full Text] [Related]
17. In vitro peptide immunization of target tax protein human T-cell leukemia virus type 1-specific CD4+ helper T lymphocytes.
Kobayashi H; Ngato T; Sato K; Aoki N; Kimura S; Tanaka Y; Aizawa H; Tateno M; Celis E
Clin Cancer Res; 2006 Jun; 12(12):3814-22. PubMed ID: 16778109
[TBL] [Abstract][Full Text] [Related]
18. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
Blejer JL; Saguier MC; Salamone HJ; Carreras LA
Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
[TBL] [Abstract][Full Text] [Related]
19. Regulation of human T-lymphotropic virus type I latency and reactivation by HBZ and Rex.
Philip S; Zahoor MA; Zhi H; Ho YK; Giam CZ
PLoS Pathog; 2014 Apr; 10(4):e1004040. PubMed ID: 24699669
[TBL] [Abstract][Full Text] [Related]
20. Serological and Molecular Methods to Study Epidemiological Aspects of Human T-Cell Lymphotropic Virus Type 1 Infection.
Cassar O; Gessain A
Methods Mol Biol; 2017; 1582():3-24. PubMed ID: 28357658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
